Palmitoyl Ethanolamide-d5

Palmitoyl ethanolamide-d5 (PEA-d5) is intended for use as an internal standard for the quantification of PEA (Cay-90350) by GC- or LC-MS. PEA is an endogenous fatty N-acyl ethanolamine and a derivative of the endocannabinoid arachidonoyl ethanolamide (AEA, Cay-90050). It selectively activates peroxisome proliferator-activated receptor alpha (PPARalpha, EC50 = 3.1 µM) over PPARbeta/delta and PPARgamma in HeLa cells expressing the human receptors. PEA binds to RBL-2H3 basophil membranes (IC50 = 1 nM), which endogenously express cannabinoid 2 (CB2), but not CB1, receptors, and inhibits antigen-induced serotonin release from RBL-2H3 cells (EC50 = 0.27 µM). It prevents decreases in paw withdrawal latency in a radiant heat hypersensitivity test, an effect that can be reversed by the CB1 receptor antagonist SR141716 (rimonabant, Cay-9000484), PPARgamma antagonist GW 9662 (Cay-70785), and transient receptor potential vanilloid 1 (TRPV1) antagonist capsazepine (Cay-10007518), in a mouse model of neuropathic pain induced by chronic constriction injury of the sciatic nerve. PEA (10 mg/kg) decreases carrageenan-induced paw edema in wild-type, but not Ppara-/-, mice. It inhibits tonic convulsions induced by pentylenetetrazole (PTZ, Cay-18682) in rats when administered at a dose of 40 mg/kg. Formulations containing palmitoyl ethanolamide have been used as dietary supplements.Formal Name: N-(2-hydroxyethyl)-hexadecanamide-15,15,16,16,16-d5. Synonyms: Palmidrol-d5, PEA-15,15,16,16,16-d5. Molecular Formula: C18H32D5NO2. Formula Weight: 304.5. Purity: >99% deuterated forms (d1-d5). Formulation: (Request formulation change), A solution in ethanol. Solubility: DMF: 2 mg/ml, Ethanol: 5 mg/ml. SMILES: O=C(NCCO)CCCCCCCCCCCCCC([2H])([2H])C([2H])([2H])[2H]. InChi Code: InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)/i1D3,2D2. InChi Key: HXYVTAGFYLMHSO-ZBJDZAJPSA-N.